Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP5 | P45974 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 8/20 | 0.41 |
| ▸ | MMP3 | P08254 | 8/20 | 0.41 |
| ▸ | MMP13 | P45452 | 8/20 | 0.41 |
| ▸ | MMP7 | P09237 | 7/20 | 0.41 |
| ▸ | MMP9 | P14780 | 6/20 | 0.41 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4670810 | 0.89 | USP5 (0.42) | USP5CCR1NAMPTNPC1MAPT | |
| SCHEMBL4670813 | 0.89 | USP5 (0.42) | USP5CCR1NAMPTNPC1MAPT | |
| SCHEMBL7504893 | 0.87 | MMP1 (0.39) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL4670994 | 0.87 | MMP1 (0.39) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL7499676 | 0.86 | MMP1 (0.41) | USP5MMP1MMP3MMP13MMP7 | |
| SCHEMBL4676908 | 0.86 | MMP1 (0.41) | USP5MMP1MMP3MMP13MMP7 | |
| SCHEMBL7453945 | 0.86 | MMP13 (0.38) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL4674806 | 0.86 | MMP13 (0.38) | MMP1MMP3MMP13MMP7MMP9 | |
| SCHEMBL4730983 | 0.85 | USP5 (0.36) | USP5MMP3CCR1NAMPTNPC1 | |
| SCHEMBL4676535 | 0.83 | MMP1 (0.52) | USP5MMP1MMP3MMP13MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | claimed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | claimed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | claimed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | claimed |
| EP-0958287-B2 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | EP | disclosed |
| EP-0958287-B1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2002-09-11 | — | — | EP | disclosed |
| US-6376506-B1 | REACTING SULFAMOYL OXAZOLIDONE WITH (1,2,3,4)-TETRAHYDRO-BETA-CARBOLINE TO FORM INHIBITOR; USED TO TREAT ARTHRITIS, OSTEOPOROSIS, PERIODONTAL DISEASE, CARDIOVASCULAR DISEASES, MULTIPLE SCLEROSIS, AND TUMORS | SYNTEX (U.S.A.) LLC | 2002-04-23 | — | — | US | disclosed |
| US-6143744-A | Sulfamide-metalloprotease inhibitors | SYNTEX (U.S.A.) INC. (US) | 2000-11-07 | — | — | US | disclosed |
| US-6130220-A | ENZYME INHIBITORS | SYNTEX (USA) INC. (US) | 2000-10-10 | — | — | US | disclosed |
| US-5998412-A | ANTIARTHRITIC AGENTS; OSTEOPOROSIS | SYNTEX (U.S.A.) INC. (US) | 1999-12-07 | — | — | US | disclosed |
| EP-0958287-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1999-11-24 | — | — | EP | disclosed |
| WO-1998032748-A1 | SULFAMIDE-METALLOPROTEASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-30 | — | — | WO | disclosed |